Maxigen Biotech Inc
TWSE:1783
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.1
50.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Maxigen Biotech Inc
Maxigen Biotech Inc
Cost of Revenue
Maxigen Biotech Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Maxigen Biotech Inc
TWSE:1783
|
Cost of Revenue
-NT$188.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
G
|
Grape King Bio Ltd
TWSE:1707
|
Cost of Revenue
-NT$2.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-13%
|
|
|
Maywufa Co Ltd
TWSE:1731
|
Cost of Revenue
-NT$501.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Chlitina Holding Ltd
TWSE:4137
|
Cost of Revenue
-NT$701.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
Maxigen Biotech Inc
Glance View
Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
See Also
What is Maxigen Biotech Inc's Cost of Revenue?
Cost of Revenue
-188.9m
TWD
Based on the financial report for Sep 30, 2024, Maxigen Biotech Inc's Cost of Revenue amounts to -188.9m TWD.
What is Maxigen Biotech Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
Over the last year, the Cost of Revenue growth was 8%. The average annual Cost of Revenue growth rates for Maxigen Biotech Inc have been 8% over the past three years , 4% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet